TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Safe Environment for Every Kid (SEEK) I: Preventing Child Maltreatment - A Role for Pediatrics
Brief Summary: This study aims to enhance pediatric primary care to make it more responsive to psychosocial needs facing many families. We hypothesized that by identifying and addressing certain problems, such as depressed mothers, parental drug use, and domestic violence, we would help decrease child abuse and neglect.


Options:
A: Inclusion Criteria:

* Age 16 years and older
* NFP program participants (woman with first live birth and living in poverty)
* English speaker

Exclusion Criteria:

- Woman who cannot communicate in English
B: Inclusion Criteria:

* Child 0 - 5 years
* Family English speaking
* Parent agrees to participate

Exclusion Criteria:

* Child in foster care
* Another child in the family already enrolled
C: Inclusion Criteria:

1. married female aged 18-40 years
2. fluency in Hindi or Marathi
3. residence with husband in the area of study for a period of 2 months or greater
4. reports that husband engaged in either heavy drinking- past 30 day drunken behavior, or frequent drinking- 3 drinking days in past 7 days, or lifetime spousal violence perpetration
5. no plans to relocate from the area in the next year.

Exclusion Criteria:

* cognitive impairment indicated at recruitment
D: Inclusion Criteria:

* African American or Latina (by self report)
* At least 18 years of age
* English speaking
* Pregnant less than or equal to 28 weeks gestation
* Receiving prenatal care in the District of Columbia
* Had one or more of the following risk factors: active smoking, environmental tobacco smoke exposure, depression and intimate partner violence

Exclusion Criteria:

* Non-minority race (by self report)
* Younger than 18 years of age
* Non-English speaking
* Not pregnant or pregnant greater than 28 weeks gestation
* Receiving prenatal care outside the District of Columbia
* Responded negatively to questions about risk factors
* Suicidal ideation

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Safe Environment for Every Kid (SEEK) I: Preventing Child Maltreatment - A Role for Pediatrics
Brief Summary: This study aims to enhance pediatric primary care to make it more responsive to psychosocial needs facing many families. We hypothesized that by identifying and addressing certain problems, such as depressed mothers, parental drug use, and domestic violence, we would help decrease child abuse and neglect.


Options:
A: Inclusion Criteria:

* Child 0 - 5 years
* Family English speaking
* Parent agrees to participate

Exclusion Criteria:

* Child in foster care
* Another child in the family already enrolled
B: Inclusion Criteria:

* Ages 18-44
* Currently in heterosexual relationship with a male partner
* Responds in affirmative to past year sexual or physical violence

Exclusion Criteria:

* Cognitive impairment (slurred speech, inability to follow directions)
* Seeking treatment for life threatening emergency care
* Intends to relocate within 2 years.
C: Inclusion Criteria:

* Caregivers of children aged 2 months to 10 years who present for well-child care visit at a pediatric clinic

Exclusion Criteria:

* Non-English speaking
* Foster parents
* Previously enrolled parent
* No access to telephone
D: Inclusion Criteria:

* Age 16 years and older
* NFP program participants (woman with first live birth and living in poverty)
* English speaker

Exclusion Criteria:

- Woman who cannot communicate in English

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to determine whether a technique using very small stitches when closing a midline incision can reduce the risk for wound complications such as incisional hernia, infection or dehiscence.


Options:
A: Inclusion Criteria:

* surgical pathologies accessed via midline or transverse abdominal incision
* primary fascial closure

Exclusion Criteria:

* pregnancy
* age under 18 years
* open abdominal treatment
* known hypersensitivity against PDS/Triclosan
B: Inclusion Criteria:

* Male or female patient with an acute or planned operation trough a midline incision at the Surgical Department in Sundsvall, Sweden

Exclusion Criteria:

* Age under 18
* Previous surgery through a midline incision
* Scars from previous surgery crossing the midline
* Preexisting hernia in the midline (umbilical, epigastric)
C: Inclusion criteria

* Signed informed consent
* All laparotomies with a midline incision
* Age \> 18 years

Exclusion criteria

* Previous incisional hernia after midline incision
* Previous surgery through a midline incision within 3 months
* Pregnancy (in women)
D: Inclusion Criteria:

* Primary ventral hernia repair performed in the region of Zealand in Denmark

Exclusion Criteria:

* Patients who died and patients not resident in region Zealand

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Mobilizing Peer Support for Effective Heart Failure Self-Management
Brief Summary: Heart failure (HF) patients living in low-income or isolated areas may have limited access to necessary clinic services and more difficulty in self-managing their illness. This study will evaluate a program that combines group health care visits and a peer-to-peer telephone buddy system at improving health outcomes among low-income and racial minority HF patients.


Options:
A: Inclusion Criteria:

* adults of any age and gender in NYHA (New York Heart Association) classes II, III, IV, assisted exclusively at home;
* willingness and ability to sign a written informed consent;
* presence of a person who cared for the patient in a prevalent and regular way;
* willingness of the caregiver to attend a training meeting.
B: Inclusion Criteria:

* age ≥65 years
* community-dwelling
* confirmed diagnosis of AF
* a CHA2DS2-VASc score of ≥1 in men and ≥2 in women
* no use of OAC therapy

Exclusion Criteria:

* impaired communication or cognitive abilities (i.e., an Abbreviated Mental Test score ≤6)
* or severe co-existing medical conditions (e.g., terminal illness) that would hinder participation in research activities
C: Inclusion Criteria:

* Age 18 year old or over.
* Patient with coronary artery disease, including Acute Coronary Syndrome (Unstable Angina, Myocardial infarction with or without ST elevation) or stable coronary vessel disease diagnosed by angiography or a stress test.
* Patient treated medically (i.e., medication only) or by thrombolysis, angioplasty, or revascularization surgery.
* Patient with physician referral, that can start CR between 2 weeks and 2 months from their event, diagnosis or procedure.
* Patient able to attend the health center almost twice a week over three months.
* Patient owns a mobile phone.
* Patient that consents to participate in the study through signing an informed consent form.

Exclusion Criteria:

* Patient has a planned repeat cardiac or other procedure in next 12 months.
* Explicit contraindication to perform exercise based on American College of Sport Medicine.
* Patients with comorbidities that would interfere with ability to engage in cardiac rehabilitation such as dementia, blindness, deafness, serious mental illness, or frailty.
* Musculoskeletal disease that precludes the patient from performing exercise
D: Inclusion Criteria:

* Diagnosed with HF
* Inpatient Hospital stay or Heart Failure Clinic Appointment

Exclusion Criteria:

* Serious mental illness or cognitive dysfunction
* Does not speak English fluently
* Receives most HF care outside the St. Joseph Mercy Health System
* Unable to use the telephone to access the IVR system
* Will be discharged to a long-term care or hospice facility
* End-stage cancer or other end-stage condition

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Mobilizing Peer Support for Effective Heart Failure Self-Management
Brief Summary: Heart failure (HF) patients living in low-income or isolated areas may have limited access to necessary clinic services and more difficulty in self-managing their illness. This study will evaluate a program that combines group health care visits and a peer-to-peer telephone buddy system at improving health outcomes among low-income and racial minority HF patients.


Options:
A: Inclusion Criteria:

1. At least 40 years old.
2. Diagnosed with Type 2 diabetes at least 1 year ago.
3. Attending the clinic for a routine diabetes follow-up visit.
4. Completed at least 2 clinic visits in the past 12 months.
5. Glycosylated hemoglobin A1c equal or greater than 8.0%
6. Owns a DVD player and television at home
7. Willing to provide informed consent.

Exclusion Criteria:

1. Primary language other than English.
2. Severe visual impairment
3. Currently enrolled in a diabetes education or support program, or participated in a diabetes education or support program in the last 6 months.
B: Inclusion Criteria:

* Diabetes with most recent HbA1c 8 or above in past 6 months.

Exclusion Criteria:

* Dementia,
* Life expectancy less than 6 months,
* Inability to speak English or Spanish.
C: Inclusion Criteria:

* Diagnosed with HF
* Inpatient Hospital stay or Heart Failure Clinic Appointment

Exclusion Criteria:

* Serious mental illness or cognitive dysfunction
* Does not speak English fluently
* Receives most HF care outside the St. Joseph Mercy Health System
* Unable to use the telephone to access the IVR system
* Will be discharged to a long-term care or hospice facility
* End-stage cancer or other end-stage condition
D: Inclusion Criteria:

* All patients in primary care referred to Diabetes Educator

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: This study examined the benefit of continued treatment with an antidepressant medication, sertraline, in adolescents with depression who improved on sertraline acutely. We hypothesize that adolescents who remained on sertraline long term were less likely to have a recurrence of depression compared to those on placebo.


Options:
A: * between the ages of 12 and 18 years 11 months
* currently in treatment for depression
* taking Prozac,Zoloft, Luvox, Lexapro, Celexa or Paxil (Oregon and Rhode Island sites only)
* still feeling depressed
B: Inclusion Criteria:

* Age 13-19
* Diagnosis of Major Depression

Exclusion Criteria:

* History of mania/hypomania
* Current psychotic symptoms
* Substance dependence
* Medical conditions (contraindication for sertraline)
* Pregnancy
* Past treatment with sertraline
C: Inclusion Criteria:

* Primary diagnosis DSM-IV of Major Depressive Disorder, pervasive and stable; Children's Depression Rating Scale-R total score at least 45; Ages 12-17 inclusive; Grade in school: 6-12; Full-Scale IQ at least 80; Medication-free before start of study; Outpatient; Parent (or family member) involvement

Exclusion Criteria:

* Bipolar disorder; Severe Conduct Disorder; Substance Use/Abuse/Dependence; Pervasive Developmental Disorders; Thought Disorder; Suicidality or homicidality; Concurrent treatment with psychotropic drug (stable stimulant for ADHD permitted) or psychotherapy outside study; Two previous failed SSRI trials or a failed trial of CBT for depression; Intolerance to fluoxetine; Non-English speaking patient; Pregnancy or breastfeeding; No phone in home; Lack of parent or family member)involvement.
D: Inclusion Criteria:

* Diagnosis of nonpsychotic major depressive disorder at least 4 weeks prior to study entry
* Clinical Global Impression severity score of 4 or greater
* Children's Depression Rating Scale score of 40 or greater
* Currently attending school
* Willing and able to use acceptable methods of contraception, if applicable
* In good general health
* Parent or guardian willing to provide informed consent, if applicable

Exclusion Criteria:

* History of psychotic disorders
* Alcohol or substance abuse or dependence within 6 months prior to study entry
* History of anorexia nervosa or bulimia
* Chronic medical illness requiring regular medication
* Current use of medication with psychotropic effects
* First-degree relatives (e.g., mother, father, sister, brother) with bipolar I disorder
* At risk for suicide
* Failure of a previous adequate treatment with fluoxetine (defined as at least 40 mg/day for 4 weeks)
* IQ less than 80
* Pregnancy or breastfeeding

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: This study examined the benefit of continued treatment with an antidepressant medication, sertraline, in adolescents with depression who improved on sertraline acutely. We hypothesize that adolescents who remained on sertraline long term were less likely to have a recurrence of depression compared to those on placebo.


Options:
A: Inclusion Criteria:

* Primary diagnosis DSM-IV of Major Depressive Disorder, pervasive and stable; Children's Depression Rating Scale-R total score at least 45; Ages 12-17 inclusive; Grade in school: 6-12; Full-Scale IQ at least 80; Medication-free before start of study; Outpatient; Parent (or family member) involvement

Exclusion Criteria:

* Bipolar disorder; Severe Conduct Disorder; Substance Use/Abuse/Dependence; Pervasive Developmental Disorders; Thought Disorder; Suicidality or homicidality; Concurrent treatment with psychotropic drug (stable stimulant for ADHD permitted) or psychotherapy outside study; Two previous failed SSRI trials or a failed trial of CBT for depression; Intolerance to fluoxetine; Non-English speaking patient; Pregnancy or breastfeeding; No phone in home; Lack of parent or family member)involvement.
B: * between the ages of 12 and 18 years 11 months
* currently in treatment for depression
* taking Prozac,Zoloft, Luvox, Lexapro, Celexa or Paxil (Oregon and Rhode Island sites only)
* still feeling depressed
C: Inclusion Criteria:

* Age 13-19
* Diagnosis of Major Depression

Exclusion Criteria:

* History of mania/hypomania
* Current psychotic symptoms
* Substance dependence
* Medical conditions (contraindication for sertraline)
* Pregnancy
* Past treatment with sertraline
D: Inclusion Criteria:

* Patient must meet Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) diagnostic criteria for Major Depressive Disorder.
* Patient's current depressive episode must be at least 12 weeks in duration
* Patient must have a parent or caregiver who must agree to accompany the patient to all clinic visits.

Exclusion Criteria:

* Patients who currently meet DSM-IV criteria for:

  1. attention deficit-hyperactivity disorder
  2. obsessive-compulsive disorder
  3. posttraumatic stress disorder
  4. bipolar disorder
  5. pervasive developmental disorder
  6. mental retardation
  7. conduct disorder
  8. oppositional defiant disorder
* Patients who are considered a suicide risk (have active suicidal ideation), who have made a suicide attempt, or who have ever been hospitalized because of a suicide attempt.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Mass-Drug Administration With a Gametocytocidal Drug Combination, a Model for a Transmission Blocking Vaccine
Brief Summary: In the 1950s, the WHO included mass drug administration (MDA) with antimalarial drugs as a tool for malaria control in 'exceptional conditions when conventional control strategies have failed'. Subsequently, MDA has received little attention until the introduction of artemisinin based combination therapy (ACT). The principle aim of MDA is to interrupt malaria transmission by clearing the population of sexual stage parasites, gametocytes, prior to the transmission season. Gametocytes are essential for propagation of the disease and elimination of gametocytes will result in a reduction in malaria transmission. As a consequence, a successful MDA will reduce the burden of disease in a population and is expected to have little influence on the development of protective immunity in areas of low transmission intensity. In Africa, only one large scale MDA study was conducted in the last 10 years. That study, conducted in The Gambia using sulphadoxine-pyrimethamine (SP) plus a single dose of artesunate (AS), failed to show a significant impact of MDA on malaria transmission. Possible reasons for this failure are the limited impact of the drug regimen (a single dose of AS) on malaria transmission, the incomplete coverage, the relatively high transmission intensity in the area and the migration of individuals between villages. Here, we propose to conduct an MDA study in an area of very low malaria transmission intensity in Tanzania. We use the highly active drug combination SP+AS (3 days) followed by a single dose of primaquine..


Options:
A: Inclusion Criteria:

* Enrolled in primary school, and attending regularly
* Enrolled in nursery or classes 1-7
* Informed consent from parent or guardian

Exclusion Criteria:

* Enrolled in primary class 8
* Haemoglobin level below 70g/L at baseline
* History of reaction to sulfa drugs (e.g. fansidar, septrin)
* History of severe skin reaction to any drug

Withdrawal criteria:

* Withdrawal of parental consent
* Haemoglobin level falling below 70g/L
* Severe adverse reaction to treatment
B: Inclusion Criteria:

1. Age between 3 months and 5 years at enrolment.
2. Informed consent obtained from parents or legal guardians.
3. No current participation in another malaria intervention trial.

Exclusion Criteria:

1. Previous adverse reaction to treatment with SP or amodiaquine. If this is unknown, then a history of allergic reaction to any drug.
C: Inclusion Criteria:

* permanent resident of the research area
* age \>1 years

Exclusion Criteria:

* severe anemia
* pregnancy
D: Inclusion Criteria:

* Children between the ages of 3-59 months resident in the selected communities
* Children likely to be available for follow-up for 18 months
* Consent by parent/guardian of child

Exclusion Criteria:

* Chronic illness
* History of hypersensitivity to any of the study drugs

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy of Clonidine in the Treatment of Neonatal Abstinence Syndrome: A Prospective, Double Blind, Randomized Controlled Trial
Brief Summary: To test the hypothesis that the combination of the tincture of opium (DTO) and clonidine will be more effective in treating infants with neonatal abstinence syndrome (opioid withdrawal) than tincture of opium (DTO) alone.


Options:
A: Inclusion Criteria:

* Neonates of mothers who consumed opiates during pregnancy
* Born after 34 completed weeks of pregnancy
* Parents' informed consent

Exclusion Criteria:

* Preterm birth before 34 0/7 gestational weeks
* Severe malformation
* Illness requiring respiratory assistance or catecholamines
* Negative meconium drug test
B: Inclusion Criteria:

* Born at Cooper University Hospital
* Greater than or equal to 35 weeks gestation age
* Admitted to the NICU or Transitional nursery
* Mothers admitted to using illicit substances or prescription medications (which can result in withdrawal symptoms) while pregnant and/or had a positive urine drug screen during pregnancy.
* Babies being started on medication to control withdrawal symptoms of NAS.
* No congenital anomalies or neurologic condition (i.e. hypoxic-ischemic encephalopathy, seizures, meningitis etc.)

Exclusion Criteria:

* Premature infants \<35 week gestational age
* Infants with major congenital abnormalities
* Blood pressure instability
* Major medical conditions
C: Inclusion Criteria:

* Infants of corrected gestational age ≥37 weeks
* Chronic opioid exposure in utero
* Signs and symptoms of NAS requiring treatment
* 2 consecutive Finnegan scores ≥8 or any single score ≥12

Exclusion Criteria:

* Concomitant maternal benzodiazepine or alcohol use 30 days prior to enrollment
* Life-threatening congenital malformations
* Intrauterine growth retardation
* Seizure activity or congenital neurologic abnormalities
* Concomitant neonatal use of Cytochrome P450 inhibitor or inducers prior to treatment
* Inability of mother's consent due to altered mental status or comorbid psychiatric disorder
* Neonatal administration of morphine prior to enrollment into study
D: * neonates born at gestational age of 35 weeks or greater
* neonates aged 0 to 14 days
* prenatally exposed to opioids
* severe NAS defined as 2 consecutive modified Finnegan Scores (MFS) \> or = 9

Exclusion Criteria:

* \< 35 weeks gestational age
* Intrauterine growth retardation defined as \<5%tile of gestational age
* postnatal treatment with barbiturates or benzodiazepines,
* major congenital anomalies
* major concomitant medical illness requiring oxygen therapy, intravenous fluids or medications.
* breastfed infants

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi Center Dose Ranging Study of Solifenacin Succinate in Combination With Tamsulosin Hydrochloride Compared With Solifenacin Succinate Monotherapy and Tamsulosin Hydrochloride Monotherapy in Males With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
Brief Summary: The study will examine the efficacy,safety and tolerability of combination therapy of tamsulosin and solifenacin compared to placebo and monotherapy of tamsulosin and solifenacin in the treatment of males with LUTS associated with BPH.


Options:
A: Inclusion Criteria:

* Voiding and storage symptoms diagnosed as LUTS associated with BPH for ≥ 3 months
* A total International Prostate Symptom Score (IPSS) of ≥13
* A maximum urinary flow rate of ≥4.0 mL/s and ≤12.0 mL/s, with voided volume of ≥120 mL during free flow
* A micturition frequency of ≥8 and at least 2 episodes of urgency with Patient Perception of the Intensity of Urgency Scale grade 3 or 4 per day on average on the 3 day micturition diary (at randomization)

Exclusion Criteria:

* Any significant Post Void Residual volume (\>150 mL)
* A prostate with estimated weight ≥75 ml as assessed by transvesical or transrectal ultrasound
* Evidence of a symptomatic urinary tract infection
B: Inclusion Criteria:

* male patients with LUTS associated with BPH diagnosed \> 3 months
* IPSS score \> 13
* voiding and storage symptoms
* maximum flow rate of \> 4 mL/s and \< 15 mL/s

Exclusion Criteria:

* post void residual volume \> 200 mL
* symptomatic urinary tract infection
C: Inclusion Criteria:

* Symptoms of OAB (frequency more than 8 per day and Urgency more than 1 episode per day confirmed by bladder diary)

Exclusion Criteria:

* Significant hepatic or renal disease, history of radiation treatment
D: Inclusion Criteria:

* Male 40 years of age
* Clinical signs and symptoms of frequency and urgency, with or without UUI, with or without BOO, for at least three months
* Mean urinary frequency of 8 micturitions/24h verified by the Screening micturition diary

Exclusion Criteria:

* Post-void residual urine volume (PVR) of \> 200 ml as measured by an ultrasound
* Maximum urinary flow rate (Qmax) of \< 5 ml/second as measured by a flowmeter; a voided volume of 75 ml is required in order to accurately record the Qmax
* Prescribed and administered an antimuscarinic or antispasmodic within 1 month
* Prescribed and administered an a-1-adrenergic antagonist within 2 weeks

Answer: B